Evidence map›Paper›PMID 32320400›Full record

ArticlePloS one2020

High prevalence of human papillomavirus and European variants of HPV 16 infecting concomitantly to cervix and oral cavity in HIV positive women.

Milagros Pérez-Quintanilla, Rocío Méndez-Martínez, Salvador Vázquez-Vega, Raquel Espinosa-Romero, Rita Sotelo-Regil, María Delia Pérez-Montiel, Ubaldo Ramos-Alamillo, Teresita de Jesús Cabrera-López, Salim Abraham Barquet-Muñoz, Carlos Pérez-Plascencia and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Spatial Epidemiology of Human Papillomavirus Screening Coverage in Mexico, 2013-2019.Asian Pacific journal of cancer prevention : APJCP · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Milagros Pérez-QuintanillaSubdirección de Investigación Clínica, Instituto Nacional de Cancerología México (INCan), Secretaría de Salud (SSA), Mexico City, Mexico.ORCID 0000-0002-1291-4534
Rocío Méndez-MartínezUnidad de Investigación Biomédica en Cáncer, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, SS, Mexico City, Mexico.
Salvador Vázquez-VegaUnidad de Investigación en Epidemiología y Servicios de Salud (UIESS), Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.ORCID 0000-0001-7544-0906
Raquel Espinosa-RomeroServicio de Citopatología, INCan, SSA, Mexico City, Mexico.
Rita Sotelo-RegilServicio de Citopatología, INCan, SSA, Mexico City, Mexico.
María Delia Pérez-MontielServicio de Patología Quirúrgica, INCan, SSA, Mexico City, Mexico.
Ubaldo Ramos-AlamilloServicio de Ginecología, Clínica Especializada Condesa (CEC) de los Servicios de Salud Pública del Distrito Federal, SSA, Mexico City, Mexico.
Teresita de Jesús Cabrera-LópezServicio de Ginecología, Clínica Especializada Condesa (CEC) de los Servicios de Salud Pública del Distrito Federal, SSA, Mexico City, Mexico.
Salim Abraham Barquet-MuñozServicio de Ginecología Oncológica, INCan, SSA, Mexico City, México.ORCID 0000-0002-3950-157X
Carlos Pérez-PlascenciaUnidad de Genómica y Cáncer, Subdirección de Investigación Básica, INCan, SSA and Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0002-8593-8211
Alejandro García-CarrancáUnidad de Investigación Biomédica en Cáncer, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, SS, Mexico City, Mexico.
David Cantú de LeónSubdirección de Investigación Clínica, INCan, SSA, México City, Mexico.ORCID 0000-0002-0229-7931
Instituto Nacional de Cancerología · MXMexican Social Security Institute · MXSecretaria de Salud · MXUniversidad Autónoma de Sinaloa · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIdentify the prevalence of HPV infections in the uterine cervix and oral cavity and HPV16 variants in HIV+ women.

methodsA total of 174 HIV+ women attended an HIV+ specialized clinic in Mexico City. Cells were obtained from the oral cavity and cervix to extract DNA. Polymerase chain reaction (PCR) was used to amplify the HPV sequence with generic primers. We detected specific HPV types using the INNO-LiPA HPV Genotyping Extra II Kit (INNOGENETICS). The identification of variants was studied by sequencing the E6 gene with a Big Dye Terminator Kit and an Applied Biosystems 3500/3500xL genetic analyzer.

resultsHPV infection was very high in the uterine cervix (168/174, 96.6%) and oral cavity (161/174, 92.5%). The prevalence of HPV concurrent infections in the cervix and oral cavity was 155/174 (89.1%). We found hrHPVs to be more prevalent than low-risk HPVs (lrHPVs) in the oral cavity (90.2% versus 45.4%) and that infections simultaneously affected the cervix (94.3% versus 36.2%) and oral cavity (85.1% versus 20.1%). Surprisingly, only European variants of HPV type 16 were found in the uterine cervix of women and the oral cavity of all tested samples (52 oral cavity samples and 52 uterine cervix samples).

conclusionsThe high prevalence of HPV, multiple infections and presence of the EP350G intravariant in both anatomical regions are strongly related to the persistence of the virus, which is fundamental for the development of cancer. Therefore, it is very important to control and monitor this high-risk population as well as implement programs for the early detection of HPV and vaccination.

Indexed as

AdultAge FactorsCervix UteriDNA, ViralFemaleHIV InfectionsHuman papillomavirus 16HumansMexicoMiddle AgedMouthOncogene Proteins, ViralPapillomavirus InfectionsPrevalenceRepressor ProteinsRisk FactorsDNA, ViralE6 protein, Human papillomavirus type 16Oncogene Proteins, ViralRepressor Proteins

Identifiers

PMID32320400
PMCPMC7176371
OpenAlexW3016694539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.